ConductScience.org, home

Paper36924668

Optically activated MEK1/2 inhibitors (Opti-MEKi) as potential antimelanoma agents.

Hao C and 5 others. Eur J Med Chem, 2023. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Optically activated MEK1/2 inhibitors (Opti-MEKi) as potential antimelanoma agents. Papers, record 36924668. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36924668

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Optically activated MEK1/2 inhibitors (Opti-MEKi) as potential antimelanoma agents.
PubMed
Journal
Eur J Med Chem
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.64
iCite
Revised in PubMed
2023-04-04
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hao CChenzhou
2Li XXiaofeng
3Wang ZZhunchao
4Liu LLihong
5He FFengli
6Pan ZZhengying

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ZebrafishMajor topic
MelanomaMajor topic
Animals
Humans
MAP Kinase Kinase 1
MAP Kinase Signaling System
Phosphorylation
Xenograft Model Antitumor Assays
Protein Kinase Inhibitors

Source PubMed

Download CSV of topics

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42883213Small-Molecule Drugs Approved by the FDA in 2025.Molecules2026https://conductscience.org/library/papers/42883213PubMed
42477424Metal-free strategy for C-N cross-coupling of benzamide with sulfonamide enabled by a Smiles rearrangement.Commun Chem2026https://conductscience.org/library/papers/42477424PubMed
41584508Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives.EXCLI J2025https://conductscience.org/library/papers/41584508PubMed
41041285Medicinal chemistry perspectives on anticancer drug design based on clinical applications (2015-2025).RSC Adv2025https://conductscience.org/library/papers/41041285PubMed
40191311BRAFPred: A Novel Approach for Accurate Prediction of the B-Type Rapidly Accelerated Fibrosarcoma Inhibitor.ACS Omega2025https://conductscience.org/library/papers/40191311PubMed
37892237Navigating the ERK1/2 MAPK Cascade.Biomolecules2023https://conductscience.org/library/papers/37892237PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
MAP2K15604PubTator's text mininghttps://conductscience.org/library/genes/5604NCBI Gene
MAP2K25605PubTator's text mininghttps://conductscience.org/library/genes/5605NCBI Gene
MAP2K75609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
ZHX222882PubTator's text mininghttps://conductscience.org/library/genes/22882NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36924668

GET https://conductscience.org/api/papers/v1/36924668/authors